According to reports from Business Standard, Ajooni Biotech experienced a significant decline in profitability during the June 2026 quarter, with net profit falling 44.87% to ₹0.43 crore compared to ₹0.78 crore in the same quarter of the previous year. Despite this profit decline, the company demonstrated strong revenue momentum with sales rising 103.04% to ₹63.49 crore in Q1 FY2026-27, up from ₹31.27 crore in Q1 FY2025-26.
As reported by Business Standard, the company's operating profit margin (OPM) improved to 2.63% in the June 2026 quarter compared to 2.27% in the corresponding quarter of the previous year. PBDT (Profit Before Depreciation and Tax) increased 14% to ₹1.46 crore from ₹1.28 crore year-on-year, while PBT (Profit Before Tax) declined 36% to ₹0.66 crore from ₹1.03 crore in Q1 FY2025-26. The company's PBDT margin remained stable at 2.33% compared to 2.27% in the previous year's corresponding quarter.
According to Business Standard, the mixed financial performance reflects the company's transition phase as it scales operations. The substantial revenue growth of 103% indicates strong business expansion, while the 45% decline in net profit suggests challenges in converting increased sales into higher profitability. The company's ability to maintain stable PBDT margins despite the profit decline demonstrates operational efficiency improvements during this growth phase.
